| Literature DB >> 14509050 |
Michael Philipp1, Otto M Lesch, Max Schmauss, Matthias Dose, Thomas Glaser.
Abstract
The efficacy of flupentixol and risperidone were compared in a randomized double-blind study in 153 chronic schizophrenic patients. Flupentixol showed to be not inferior to risperidone concerning schizophrenic negative symptoms at week 8, 16 and 24. Positive symptoms and general psychopathology improved comparably, too. There was a trend in favor of flupentixol concerning the improvement of depressive symptoms and a trend in favor of risperidone concerning the improvement of preexisting parkinsonian symptoms. The study data justify to regard flupentixol as a "partial atypical" antipsychotic.Entities:
Mesh:
Substances:
Year: 2003 PMID: 14509050
Source DB: PubMed Journal: Psychiatr Prax ISSN: 0303-4259